GEN Exclusives

More »

GEN News Highlights

More »
Aug 27, 2007

BioLineRx In-Licenses Treatment for Acute Kidney Injury

  • BioLineRx signed a worldwide, exclusive license agreement with Gene Vector Technologies for the development and commercialization of BL-4040, a drug for the treatment of acute kidney injury (AKI).

    BL-4040 is a genetically engineered version of the major capsid protein VP1, derived from the outer protein shell of the virus SV40. By boosting the natural stress response and survival pathways of kidney cells, BL-4040 may prevent apoptosis of kidney cells following AKI, the companies explain.

    “BL-4040 is extremely effective in mice, relatively simple to produce, and nontoxic even at very high doses,” says Morris C. Laster, M.D., CEO of BioLineRx. “We believe that BL-4040 offers the potential for a highly effective and safe therapy that taps into the natural defense systems of the body.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »